A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia: SWOG S0703 protocol—Report on the good-risk patients.
Sucha Nand
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Holly Gundacker
No relevant relationships to disclose
John E. Godwin
No relevant relationships to disclose
Cheryl L. Willman
No relevant relationships to disclose
Thomas Norwood
No relevant relationships to disclose
Harry Paul Erba
No relevant relationships to disclose
Dianna S. Howard
No relevant relationships to disclose
Steven E. Coutre
No relevant relationships to disclose
Megan Othus
No relevant relationships to disclose
Frederick R. Appelbaum
No relevant relationships to disclose